Viridian Therapeutics Stock Up 75%, but One Fund Just Sold Off Its $69 Million Stake
2026-02-23 10:46:08 ET
On February 17, 2026, Commodore Capital disclosed in an SEC filing that it sold out its entire 3,200,000-share position in Viridian Therapeutics (NASDAQ:VRDN) , an estimated $69.06 million transaction based on last-disclosed position values.
According to a filing with the Securities and Exchange Commission dated February 17, 2026, Commodore Capital reported selling its entire 3,200,000-share stake in Viridian Therapeutics. The net position change for the quarter was $69.06 million, reflecting the removal of the holding from the portfolio.
Viridian Therapeutics, Inc. is a clinical-stage biotechnology company specializing in the development of innovative antibody-based therapies for serious diseases, with a lead focus on thyroid eye disease. The company leverages expertise in monoclonal antibody engineering to advance its pipeline and address unmet medical needs in rare disorders. With a growing portfolio and a targeted approach to specialty markets, Viridian aims to establish a competitive position in the biotechnology sector through differentiated therapeutics and clinical progress.
NASDAQ: VRDN
VRDN Trading
-1.29% G/L:
$27.445 Last:
286,450 Volume:
$27.69 Open:
